CurcuPlex-95 120 C by Xymogen

CurcuPlex-95 120 C

Xymogen

$90.99
(No reviews yet) Write a Review
SKU:
XY-CURC95-120-1
Availability:
Usually Ships in 48 to 72 Hours
Already Registered?
How to Gain Access to Store?

CurcuPlex-95 120 C by Xymogen 

CurcuPlex-95 120c is an anti-oxidative supplement designed by Xymogen.* Apart from its impact on antioxidation, it may have a plethora of other effects on your body, including supporting your mental health and cell growth or even alleviating minor pains during physical activity.*

Who Should Consider CurcuPlex-95 120 Capsules?

CurcuPlex-95 120 capsules may be for you if:

  • you do a lot of physical exercises and want to feel better after each workout*
  • you want to improve your overall health*

CurcuPlex-95 120 Capsules by Xymogen—Effects

CurcuPlex-95 120c by Xymogen may:

  • support antioxidation*
  • promote joint health*
  • relieve minor pain*
  • support a healthy microbial environment*
  • support brain/neuronal health and mood*
  • promote cellular energy production and inhibit unhealthy cell growth in certain cell lines*

Supplements support your health but do not replace a balanced diet. Always check with your healthcare practitioner if you have doubts about a new supplement. Book a FREE product consultation to learn more about CurcuPlex-95 120 capsules.

Recommendation:
Xymogen suggests, as a dietary supplement, taking one CurcuPlex-95 capsule twice daily, or as directed by your healthcare practitioner.

Serving Size: 1 Capsule
Servings per Container: 120

Amount per Serving:
Turmeric Extract (Curcuma longa)(rhizome)(95% total curcuminoids complex, including curcumin, curcuminoids, and volatile oils)(86% curcuminoids)(65% curcumin)S1 500 mg

Other Ingredients: Capsule (hypromellose and water), dicalcium phosphate, ascorbyl palmitate, silica, and carboxymethyl cellulose.

Storage:
Keep closed in a cool, dry place out of reach of children.

Does Not Contain: Wheat, gluten, corn, yeast, soy, animal or dairy products, fish, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, or artificial preservatives.

S1. BCM-95® is an exclusivity licensed registered trademark to Arjuna Natural Pvt Ltd. Protected under U.S. Patents 7,883,728; 7,736,679; and 7,879,373.

All XYMOGEN Formulas Meet or Exceed cGMP Quality Standards.

© 2015. XYMOGEN®. All rights reserved.

*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Click here to view Data Sheet

LEGAL NOTICE: Xymogen's Exclusive Professional Formulas are available through select licensed health care professionals. The Internet Sale and Discounting of XYMOGEN formulas are strictly prohibited. covenanthealthproducts.com makes XYMOGEN formulas available only to patients of our clinic. If you are a patient of covenanthealthproducts.com, you may inquire about XYMOGEN by calling (800) 627-6518

References:

  1. Here are the references formatted in APA 7th edition style, organized alphabetically:
  2. Antony, B., Merina, B., Iyer, V. S., et al. (2008). A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian Journal of Pharmaceutical Sciences, 70(4), 445–449. [PMID: 20046768]
  3. Baum, L., Cheung, S. K., Mok, V. C., et al. (2007). Curcumin effects on blood lipid profile in a 6-month human study. Pharmacological Research, 56(6), 509–514. [PMID: 17951067]
  4. Baum, L., Lam, C. W., Cheung, S. K., et al. (2008). Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. Journal of Clinical Psychopharmacology, 28(1), 110–113. [PMID: 18204357]
  5. Buhrmann, C., Kraehe, P., Lueders, C., et al. (2014). Curcumin suppresses crosstalk between colon cancer stem cells and stromal fibroblasts in the tumor microenvironment: Potential role of EMT. PLoS One, 9(9), e107514. [PMID: 25238234]
  6. Chandran, B., & Goel, A. (2012). A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytotherapy Research, 26(11), 1719–1725. [PMID: 22407780]
  7. Cheng, A. L., Hsu, C. H., Lin, J. K., et al. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Research, 21(4B), 2895–2900. [PMID: 11712783]
  8. Garcea, G., Berry, D. P., Jones, D. J., et al. (2005). Consumption of the putative chemopreventive agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiology, Biomarkers & Prevention, 14(1), 120–125. [PMID: 15668484]
  9. Ghosh, S., Banerjee, S., & Sil, P. C. (2015). The beneficial role of curcumin on inflammation, diabetes, and neurodegenerative disease: A recent update. Food and Chemical Toxicology, 83, 111–124. [PMID: 26066364]
  10. Hejazi, J., Rastmanesh, R., Forough-Azam, T., et al. (2013). A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer. Journal of Cancer Science & Therapy, 5(10), 320–324. [http://www.omicsonline.org/a-pilot-clinical-trial-of-radioprotective-effects-of-curcumin-supplementation-in-patients-with-prostate-cancer-1948-5956.1000222.php?aid=19259]
  11. Honda, S., Aoki, F., Tanaka, H., et al. (2006). Effects of ingested turmeric oleoresin on glucose and lipid metabolisms in obese diabetic mice: A DNA microarray study. Journal of Agricultural and Food Chemistry, 54(24), 9055–9062. [PMID: 17117790]
  12. Jiang, J., Eliaz, I., & Sliva, D. (2011). Suppression of growth and invasive behavior of human prostate cancer cells by ProstaCaid™: Mechanism of activity. International Journal of Oncology, 38(6), 1675–1682. [PMID: 21468543]
  13. Jiang, J., Loganathan, J., Eliaz, I., et al. (2012). ProstaCaid inhibits tumor growth in a xenograft model of human prostate cancer. International Journal of Oncology, 40(5), 1339–1344. [PMID: 22293856]
  14. Kizhakkedath, R. (2013). Clinical evaluation of a formulation containing Curcuma longa and Boswellia serrata extracts in the management of knee osteoarthritis. Molecular Medicine Reports, 8(5), 1542–1548. [PMID: 24002213]
  15. Leray, V., Freuchet, B., Le Bloc’h, J., et al. (2011). Effect of citrus polyphenol- and curcumin-supplemented diet on inflammatory state in obese cats. British Journal of Nutrition, 106(Suppl 1), S198–S201. [PMID: 22005428]
  16. Lopresti, A. L., Maes, M., Maker, G. L., et al. (2014). Curcumin for the treatment of major depression: A randomised, double-blind, placebo-controlled study. Journal of Affective Disorders, 167, 368–375. [PMID: 25046624]
  17. Lopresti, A. L., Maes, M., Meddens, M. J., et al. (2015). Curcumin and major depression: A randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change. European Neuropsychopharmacology, 25(1), 38–50. [PMID: 25523883]
  18. Nishiyama, T., Mae, T., Kishida, H., et al. (2005). Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. Journal of Agricultural and Food Chemistry, 53(4), 959–963. [PMID: 15713005]
  19. Sanmukhani, J., Anovadiya, A., & Tripathi, C. B. (2011). Evaluation of antidepressant-like activity of curcumin and its combination with fluoxetine and imipramine: An acute and chronic study. Acta Poloniae Pharmaceutica, 68(5), 769–775. [PMID: 21928724]
  20. Sanmukhani, J., Satodia, V., Trivedi, J., et al. (2014). Efficacy and safety of curcumin in major depressive disorder: A randomized controlled trial. Phytotherapy Research, 28(4), 579–585. [PMID: 23832433]
  21. Shakibaei, M., Buhrmann, C., Kraehe, P., et al. (2014). Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high-density cultures. PLoS One, 9(1), e85397. [PMID: 24404205]
  22. Shishu, M. (2010). Comparative bioavailability of curcumin, turmeric, and Biocurcumax™ in traditional vehicles using a non-everted rat intestinal sac model. Journal of Functional Foods, 2(1), 60–65.
  23. Toden, S., Okugawa, Y., Buhrmann, C., et al. (2015). Novel evidence for curcumin and boswellic acid-induced chemoprevention through regulation of mir-34a and mir-27a in colorectal cancer. Cancer Prevention Research, 8(5), 431–443. [PMID: 25712055]
  24. Toden, S., Okugawa, Y., Jascur, T., et al. (2015). Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis, 36(3), 355–367. [PMID: 25653233]
  25. Yan, J., Katz, A. E. (2010). ProstaCaid induces G2/M cell cycle arrest and apoptosis in human and mouse androgen-dependent and -independent prostate cancer cells. Integrative Cancer Therapies, 9(2), 186–196. [PMID: 20587444]
  26. Yang, F., Lim, G. P., Begum, A. N., et al. (2005). Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. Journal of Biological Chemistry, 280(7), 5892–5901. [PMID: 15590663]